title: Phosphodiesterase 4 inhibition attenuates plasma volume loss and transvascular exchange in volume-expanded mice.
abstract: We tested the hypothesis that inhibition of phosphodiesterase 4 (PDE4) with rolipram to increase vascular endothelial cAMP and stabilize the endothelial barrier would attenuate the action of endogenous atrial natriuretic peptide (ANP) to increase vascular permeability to the plasma protein albumin after an acute plasma volume expansion. After rolipram pretreatment (8 mg (kg body wt)(-1), intraperitoneal, 30 min) more than 95% of the peak increase in plasma volume after volume expansion (4.5% bovine serum albumin, 114 μl (g body wt)(-1) h(-1), 15 min) remained in the vascular space 75 min after the end of infusion, whereas only 67% of the fluid was retained in volume-expanded animals with no rolipram pretreatment. Rolipram significantly decreased 30 min fluorescently labelled albumin clearance (μl (g dry wt)(-1)) relative to untreated volume-expanded controls in skin (e.g. back, 10.4 ± 1.6 vs. 19.5 ± 3.6, P = 0.04), muscle (e.g. hamstring, 15.0 ± 1.9 vs. 20.8 ± 1.4, P = 0.04) and in colon, caecum, and rectum (average reduction close to 50%). The mass of muscle and skin tissue accounted for 70% of volume-expansion-dependent albumin shifts from plasma to interstitium. The results are consistent with observations that the PDE4 inhibitor rolipram attenuates ANP-induced increases in vascular permeability after infusion of exogenous ANP and observations of elevated central venous pressure after a similar volume expansion in mice with selective deletion of the endothelial ANP receptor. These observations may form the basis for new strategies to retain intravenous fluid containing macromolecules.
authors.affiliation: Department of Physiology and Membrane Biology, School of Medicine, 1 Shields Avenue, University of California, Davis, CA 95616, USA.
authors.forename: Yueh-Chen
authors.initials: YC
authors.lastname: Lin
authors.forename: Roger H
authors.initials: RH
authors.lastname: Adamson
authors.forename: Joyce F
authors.initials: JF
authors.lastname: Clark
authors.forename: Rolf K
authors.initials: RK
authors.lastname: Reed
authors.forename: Fitz-Roy E
authors.initials: FR
authors.lastname: Curry
mesh_terms: D000818:Animals; D009320:Atrial Natriuretic Factor / Q000378:metabolism / Q000494:pharmacology; D002199:Capillary Permeability / Q000187:drug effects* / Q000502:physiology; D002463:Cell Membrane Permeability / Q000187:drug effects / Q000502:physiology; D002496:Central Venous Pressure / Q000187:drug effects / Q000502:physiology; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4 / Q000187:drug effects*; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D023421:Models, Animal; D009206:Myocardium / Q000378:metabolism; D058988:Phosphodiesterase 4 Inhibitors / Q000494:pharmacology*; D010953:Plasma Volume / Q000187:drug effects*; D020889:Rolipram / Q000494:pharmacology*; D012709:Serum Albumin / Q000378:metabolism
chemical_list: D058988:Phosphodiesterase 4 Inhibitors; D012709:Serum Albumin; D009320:Atrial Natriuretic Factor; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D020889:Rolipram
references.citation: Am J Physiol Heart Circ Physiol. 2008 Mar;294(3):H1188-96
references.pmid: 18178724
references.citation: J Biol Chem. 2011 May 13;286(19):16681-92
references.pmid: 21454546
references.citation: Shock. 2008 Jul;30(1):55-63
references.pmid: 18323741
references.citation: Shock. 2002 Aug;18(2):138-41
references.pmid: 12166776
references.citation: Physiol Rev. 1990 Jul;70(3):665-99
references.pmid: 2141944
references.citation: Life Sci. 1981 Jan 5;28(1):89-94
references.pmid: 7219045
references.citation: Eur Heart J. 1993 Nov;14 Suppl I:141-8
references.pmid: 8293765
references.citation: Br J Pharmacol. 2001 Jun;133(4):485-94
references.pmid: 11399665
references.citation: Circ Res. 2007 Oct 12;101(8):811-8
references.pmid: 17704206
references.citation: J Clin Invest. 2005 Jun;115(6):1666-74
references.pmid: 15931395
references.citation: Anesthesiology. 2004 Nov;101(5):1136-44
references.pmid: 15505449
references.citation: Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):6215-9
references.pmid: 8650246
references.citation: Shock. 2003 Aug;20(2):149-53
references.pmid: 12865659
references.citation: Circ Res. 1987 Feb;60(2):304-7
references.pmid: 2952366
references.citation: Am J Physiol. 1986 Oct;251(4 Pt 2):H880-3
references.pmid: 2945444
references.citation: Am J Physiol. 1992 Oct;263(4 Pt 2):R945-53
references.pmid: 1415808
references.citation: Eur J Cell Biol. 2006 Jul;85(7):585-92
references.pmid: 16524641
references.citation: Am J Physiol Heart Circ Physiol. 2007 Aug;293(2):H1196-205
references.pmid: 17434979
references.citation: Inflamm Res. 1995 Feb;44(2):83-6
references.pmid: 7655990
references.citation: J Physiol. 2011 Jan 15;589(Pt 2):341-53
references.pmid: 21098005
references.citation: Eur J Pharmacol. 2002 Sep 20;451(3):295-302
references.pmid: 12242091
references.citation: Am J Physiol Regul Integr Comp Physiol. 2002 May;282(5):R1477-89
references.pmid: 11959692
references.citation: Circ Res. 2004 Apr 16;94(7):936-43
references.pmid: 14988225
references.citation: Blood. 2005 Mar 1;105(5):1950-5
references.pmid: 15374886
references.citation: Life Sci. 1986 Sep 29;39(13):1193-9
references.pmid: 2943959
references.citation: Am J Physiol. 1998 Nov;275(5):H1818-25
references.pmid: 9815090
references.citation: Am J Physiol. 1988 Feb;254(2 Pt 2):H304-12
references.pmid: 3257846
references.citation: Can J Physiol Pharmacol. 2009 Jan;87(1):1-7
references.pmid: 19142210
references.citation: Am J Physiol. 1999 Jan;276(1):H333-9
references.pmid: 9887048
references.citation: Philos Trans R Soc Lond B Biol Sci. 2004 Dec 29;359(1452):1921-30
references.pmid: 15647168
references.citation: Basic Res Cardiol. 2004 Mar;99(2):71-5
references.pmid: 14963664
references.citation: J Physiol. 2009 Feb 15;587(Pt 4):713-9
references.pmid: 19218620
references.citation: J Physiol. 2010 Jan 15;588(Pt 2):325-39
references.pmid: 19948658
references.citation: Mol Pharmacol. 2005 Jan;67(1):263-72
references.pmid: 15475573
references.citation: Br J Pharmacol. 1994 May;112(1):332-40
references.pmid: 8032659
references.citation: Crit Care. 2004 Dec;8(6):503-7
references.pmid: 15566623
references.citation: J Am Soc Nephrol. 2007 Jan;18(1):199-212
references.pmid: 17135396
references.citation: Curr Opin Cell Biol. 2005 Apr;17(2):123-8
references.pmid: 15780587
references.citation: Pharmacol Ther. 2006 Mar;109(3):366-98
references.pmid: 16102838
references.citation: Microcirculation. 1998;5(2-3):139-52
references.pmid: 9789255
references.citation: J Clin Invest. 1993 Apr;91(4):1421-8
references.pmid: 8386187
references.citation: J Physiol. 2001 Oct 15;536(Pt 2):533-9
references.pmid: 11600687
references.citation: Microcirculation. 2003 Apr;10(2):221-31
references.pmid: 12700589
references.citation: Endocrinology. 2008 Aug;149(8):4193-9
references.pmid: 18450968